-
1دورية أكاديمية
المؤلفون: Boidot, Romain1 (AUTHOR), Blum, Michael G.B.1,2 (AUTHOR) michael.blum@seqone.com, Wissler, Marie-Pierre3 (AUTHOR), Gottin, Céline2 (AUTHOR), Ruzicka, Jiri2 (AUTHOR), Chevrier, Sandy1 (AUTHOR), Delhomme, Tiffany M.2 (AUTHOR), Audoux, Jérome2 (AUTHOR), Jeanniard, Adrien4 (AUTHOR), Just, Pierre-Alexandre5 (AUTHOR), Harter, Philipp6 (AUTHOR), Pignata, Sandro7 (AUTHOR), González-Martin, Antonio8 (AUTHOR), Marth, Christian9 (AUTHOR), Mäenpää, Johanna10 (AUTHOR), Colombo, Nicoletta11 (AUTHOR), Vergote, Ignace12 (AUTHOR), Fujiwara, Keiichi13 (AUTHOR), Duforet-Frebourg, Nicolas2 (AUTHOR), Bertrand, Denis2 (AUTHOR)
المصدر: European Journal of Cancer. May2024, Vol. 202, pN.PAG-N.PAG. 1p.
مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *BRCA genes, *OVARIAN tumors, *BEVACIZUMAB, *ENZYME inhibitors, *TUMOR markers, *RETROSPECTIVE studies, *CANCER patients, *DESCRIPTIVE statistics, *DNA damage, *HUMAN genome, *CONFIDENCE intervals, *PROGRESSION-free survival, *SURVIVAL analysis (Biometry), *SEQUENCE analysis, *PROPORTIONAL hazards models
-
2دورية أكاديمية
المؤلفون: Vergote, Ignace1,2 (AUTHOR) ignace.vergote@uzleuven.be, Ray-Coquard, Isabelle3,4 (AUTHOR), Anderson, Daniel M.5 (AUTHOR), Cantuaria, Guilherme6 (AUTHOR), Colombo, Nicoletta7,8 (AUTHOR), Garnier-Tixidre, Claire4,9 (AUTHOR), Gilbert, Lucy10 (AUTHOR), Harter, Philipp11,12 (AUTHOR), Hettle, Robert13 (AUTHOR), Lorusso, Domenica14,15 (AUTHOR), Mäenpää, Johanna16,17 (AUTHOR), Marth, Christian18,19 (AUTHOR), Matsumoto, Koji20 (AUTHOR), Ouwens, Mario13 (AUTHOR), Poveda, Andrés21,22 (AUTHOR), Raspagliesi, Francesco23 (AUTHOR), Rhodes, Kirsty13 (AUTHOR), Rubio Pérez, María J.22,24 (AUTHOR), Shapira-Frommer, Ronnie25 (AUTHOR), Shikama, Ayumi26,27 (AUTHOR)
المصدر: European Journal of Cancer. Nov2021, Vol. 157, p415-423. 9p.
مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *OVARIAN tumors, *CONFIDENCE intervals, *BRCA genes, *ANTINEOPLASTIC agents, *CANCER patients, *KAPLAN-Meier estimator, *DESCRIPTIVE statistics, *BEVACIZUMAB, *ENZYME inhibitors, *SECONDARY analysis, *PROPORTIONAL hazards models